Page 1

• • • • • BLACK DIAMOND THERAPEUTICS Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Initial Phase 1 clinical PK , safety , and preliminary efficacy data for BDTX - 189 presented at ASCO Annual Meeting ; on track to initiate Phase 2 portion of MasterKey - 01 study in second half of 2021 Pre - clinical data for BDTX - 1535 presented at AACR Annual Meeting ; program on track to enter the clinic in 2022 Early - stage pipeline programs targeting BRAF and FGFR remain on track for IND filing in 2022 Biotech industry veteran Mark Velleca , M.D. , Ph.D. , appointed to Board of Directors Cash , cash equivalents , and investments of $ 263.5 million as of June 30 , 2021 , expected to be sufficient to fund operations into 2023 CAMBRIDGE , Mass . and NEW YORK , August 12 , 2021 Black Diamond Therapeutics , Inc. ( Nasdaq : BDTX ) , a precision oncology medicine company pioneering the discovery and development of small molecule , MasterKey therapies , today reported financial results for the second quarter ended June 30 , 2021 and provided a corporate update . " We continue to advance our clinical and pre - clinical pipeline of MasterKey therapies , including BDTX - 189 , for which we expect to initiate the Phase 2 trial in the second half of this year . Our early - stage programs continue to advance as well , and we look forward to submitting Investigational New Drug ( IND ) applications for our BDTX - 1535 , BRAF ( B- Raf ) , and fibroblast growth factor receptor ( FGFR ) programs in 2022 , ” said David M. Epstein , Ph.D. , President and Chief Executive Officer of Black Diamond Therapeutics . " We remain committed to the discovery and development of novel precision medicine therapies to address genetically defined cancers with unmet medical need . " Recent Developments BDTX - 189 : • Black Diamond completed the Phase 1 dose - escalation portion of the MasterKey - 01 study , a Phase 1/2 clinical trial of BDTX - 189 . The Company has selected the preliminary recommended Phase 2 dose for BDTX - 189 and , pending dialogue with the U.S. Food and Drug Administration ( FDA ) , is on track to initiate the Phase 2 portion of the study in the second half of 2021 . In May 2021 , Black Diamond presented initial clinical pharmacokinetic ( PK ) , safety , and preliminary efficacy data from the Phase 1 dose - escalation portion of the MasterKey - 01 study of BDTX - 189 in advanced solid tumors at the American Society of Clinical Oncology ( ASCO ) Annual Meeting . ° BDTX - 189 was generally well - tolerated with medically manageable toxicities observed ;